Author Claim Review

 Quick Explanation Copied

 Long Explanation

Career Profile and Citation Metrics

Linmao Zheng is affiliated with Sichuan University and has 99 indexed works with 668 total citations and an h-index of 12. Productivity accelerated sharply: only 1–4 works per year through 2023, then 58 works in 2024, of which 57 are open access OpenAlex profile for Linmao Zheng. Such a sudden output surge warrants verification for authorship-listing practices or indexing artifacts, though 2025–2026 output normalized to 6 and 4 works.

Peak citation impact came in 2021 (298 citations), driven almost entirely by two landmark rare-RCC studies TFE3-tRCC Nature Communications study FH-deficient RCC CCR study.

Scientific Contributions and Role

Zheng's work centers on molecular pathology of rare kidney and CNS tumors within a productive Sichuan University collaborative network (Guangxi Sun, Xingming Zhang, Ling Nie, Mengni Zhang, Qing Mao). In the flagship TFE3-tRCC and FH-deficient RCC studies, Zheng appears as a middle author, indicating a contributor rather than lead role; Zheng is first author on the H3 K27M diffuse midline glioma comparison (adults vs children, American Journal of Surgical Pathology, 108 citations) and the AKR1B10 biomarker study for FH-deficient RCC (Modern Pathology, 33 citations) H3 K27M DMG adult-pediatric comparison AKR1B10 biomarker study. Zheng also contributes to translational extensions: paired primary-metastatic FH-RCC sequencing Primary-metastatic FH-RCC evolution study, immunotherapy correlates in 91 FH-RCC patients FH-RCC immunotherapy response study, and a weakly supervised deep-learning glioma histopathology classifier on 472 slides Weakly supervised glioma DL study.

Critical Assessment and Blindspots

Strengths: publication venues are high quality (Nature Communications ×2, Clinical Cancer Research ×2, Cancer Research, Genome Medicine, AJSP), and the rare-tumor niche fills genuine clinical gaps (no standard therapy for advanced TFE3-tRCC or FH-RCC). Limitations: (1) most studies are single-institution retrospective cohorts from one health system, limiting generalizability; (2) rare-tumor sample sizes (e.g., 63 TFE3-tRCC primaries, 91 FH-RCC patients) constrain statistical power for subtype-level conclusions; (3) the h-index of 12 over 99 works implies a modest mean citation impact (~6.7 cites/work) concentrated in 2–3 papers, so sustained independent influence remains unproven; (4) the 2024 output spike (58 works, nearly all OA) and the absence of a recorded primary institution in OpenAlex reduce metadata reliability and merit caution; (5) Zheng is typically a middle author, so the portfolio partly reflects team productivity of the Sichuan University molecular pathology group rather than individual leadership. Confidence: moderate — this review relies solely on OpenAlex metadata and abstracts without access to full texts, author contribution statements, or independent verification of the 2024 publication spike.

 BGPT Author Review

Scientific Quality

H-index 12 with 99 works and 668 citations reflects a solid mid-career contributor embedded in a strong molecular pathology team. Two highly cited rare-RCC multi-omics papers in top venues (Nature Communications, CCR) demonstrate genuine technical skill, but Zheng is typically a middle rather than lead author, so individual scientific leadership is not yet established. The 2024 spike to 58 works is a red flag requiring verification. No evidence of misconduct, but independent impact is modest.

Communication Quality

Publications appear in accessible venues with clear clinical framing of rare tumor subtypes and gold open access for several key works, aiding dissemination. Research-extracts suggest well-structured problem-driven writing (rare cancer, unmet therapeutic need, defined cohort). No direct evidence of exceptional pedagogy or public communication; assessment is limited to abstract quality.

Author Novelty

First descriptions of molecular features in rare subtypes (TFE3-tRCC, FH-deficient RCC, adult H3 K27M gliomas), the AKR1B10 diagnostic marker proposal, and application of weakly supervised deep learning to glioma histopathology show meaningful novelty within a rare-disease niche. The core methodology (integrated exome/RNA-seq profiling) is standard, capping novelty at moderately above average.

Scientific Rigor

Studies use multi-omics integration with reasonable cohort sizes for rare tumors (63 TFE3-tRCC, 91 FH-RCC, 472 glioma slides) and reference counts consistent with thorough literature grounding. However, single-center retrospective designs, lack of prospective validation for the AKR1B10 marker, and rare-subtype power constraints limit rigor. Closed-access and metadata inconsistencies prevent full methodological audit.